SERUM ß-CRYPTOXANTHIN AS A PREDICTOR OF BONE FORMATION MARKERS IN POST-MENOPAUSAL WOMEN
F. Granado-Lorencio, F.J. García-López, E. Donoso-Navarro, I. Blanco-Navarro, B. Pérez-Sacristán
J Aging Res Clin Practice 2012;1(1):33-36
Objective: To assess the associations between fat-soluble vitamin and antioxidant status and levels of bone remodelling markers in post-menopausal women. Design: A cross-sectional study. Setting; A nutrition laboratory from a terciary hospital. Participants: Sixty-one post-menopausal women were contacted to participate in a dietary intervention trial and 36 women were finally included (age 45 to 65years, BMI <35 kg/m2, amenorrhea over 12 months, no hormone therapy, no anabolic or antiresorptive therapy). Mearurements: Baseline blood samples were processed for the assessment of retinol, α-tocopherol, 25-OH-D3, lutein/zeaxanthin, β-cryptoxanthin, lycopene, α-carotene and β-carotene (by UHPLC), parathyroid hormone and bone metabolism markers (osteocalcin, N-terminal peptide of procollagen I (P1NP) and β-crosslaps), sex hormones (17-β-estradiol, FSH, LH) and lipid profile. Results: Mean values of all the parameters except total cholesterol were within reference ranges even when mean concentrations of 25-OH-vitamin D could be considered as insufficient (mean, [95% confidence interval]: 47.7 nmol/l [41.1 to 54.2 nmol/l]). Bone remodelling markers in serum were not significantly correlated to age, age of menopause, weight, BMI, sex hormones, lipids, retinol, α-tocopherol (or α-tocopherol /cholesterol ratio) or 25-OH-vitamin D. Only crude concentrations and cholesterol-adjusted values of β-cryptoxanthin showed a positive and significant correlation with bone formation markers (r= 0.53, p=0.001 for osteocalcin; r=0.41, p=0.013 for P1NP) while lycopene showed an inverse trend with P1NP (r= -0.32, p=0.06). In the regression analysis, β-cryptoxanthin alone could explain 28% of the variation of serum osteocalcin (r2= 0.28; B= 0.60; p=0.001). Conclusion: Serum β-cryptoxanthin is a predictor of bone formation markers in post-menopausal women and dietary advice regarding β-cryptoxanthin-rich foods may be a safe and sustainable approach to improve bone health.